Moreover, a recent study reported that the upregulation of S100A9 induces pancreatic injury and an AP response via NLRP3 activation by targeting VNN1-mediated ROS release and that loss of S100A9 decreases AP injury (36). The gene discussed is VNN1; the disease is alkaline phosphatase measurement.